https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-analyst-event-rezilient3-trial BiopharmaWatch en 2026-09-10T17:00:00.000Z Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer https://www.biopharmawatch.com/news/IMNN/imunon-nci-agreement-advance-imnn-001 BiopharmaWatch en 2026-09-10T13:30:00.000Z IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001 https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-fda-approval-lytenava BiopharmaWatch en 2026-09-10T13:10:00.000Z Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment https://www.biopharmawatch.com/news/AGL/agilon-health-family-practice-center-expansion BiopharmaWatch en 2026-09-10T13:00:00.000Z agilon health and Family Practice Center Expand Relationship Through Senior Health Connect ACO https://www.biopharmawatch.com/news/CODX/co-diagnostics-vector-smart-laboratory-installations BiopharmaWatch en 2026-09-10T13:00:00.000Z Co-Diagnostics Completes New Vector Smart® Laboratory Installations Amid Rising Dengue Activity in Florida https://www.biopharmawatch.com/news/TXG/lunit-collaboration-10x-genomics-ai-pathology-oncology BiopharmaWatch en 2026-09-10T13:00:00.000Z Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research https://www.biopharmawatch.com/news/NRSN/neurosense-presentation-hc-wainwright-conference BiopharmaWatch en 2026-09-10T13:00:00.000Z NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/POCI/precision-optics-receives-follow-on-production-orders BiopharmaWatch en 2026-09-10T13:00:00.000Z Precision Optics Announces Receipt of $1.3 Million Follow-On Production Orders from Large Defense Company https://www.biopharmawatch.com/news/OMDA/omada-health-investor-day-financial-targets BiopharmaWatch en 2026-09-10T13:00:00.000Z Omada Health to Present Updated Long-Term Financial Targets at Inaugural Investor Day https://www.biopharmawatch.com/news/LITS/lite-strategy-presents-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-10T13:00:00.000Z Lite Strategy to Present at the 28th Annual H.C. Wainwright Global Investment Conference in New York https://www.biopharmawatch.com/news/BNGO/bionano-laboratories-proposed-lcd-structural-variants BiopharmaWatch en 2026-09-10T13:00:00.000Z Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms https://www.biopharmawatch.com/news/FTRE/fortrea-september-investor-conferences-2026 BiopharmaWatch en 2026-09-10T12:58:00.000Z Fortrea to Participate in September Investor Conferences https://www.biopharmawatch.com/news/ABBV/abbvie-positive-phase-3-atogepant-results-menstrual-migraine BiopharmaWatch en 2026-09-10T12:55:00.000Z AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine https://www.biopharmawatch.com/news/OPTH/optimi-health-phase-2-trial-psilocybin-mdd BiopharmaWatch en 2026-09-10T12:45:00.000Z Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder https://www.biopharmawatch.com/news/ICU/seastar-medical-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-10T12:35:00.000Z SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/HYFT/mindwalk-participate-hc-wainwright-investment-conference BiopharmaWatch en 2026-09-10T12:34:00.000Z MindWalk to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-canaccord-genuity-well-summit BiopharmaWatch en 2026-09-10T12:32:00.000Z Niagen Bioscience to Present at Canaccord Genuity’s Well Summit https://www.biopharmawatch.com/news/QTI/qt-imaging-participate-iaccess-alpha-conference BiopharmaWatch en 2026-09-10T12:30:00.000Z QT Imaging to Participate in the iAccess Alpha Virtual Best Ideas Fall Investment Conference https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-netherton-now-video-aminah-story BiopharmaWatch en 2026-09-10T12:30:00.000Z Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU https://www.biopharmawatch.com/news/BCDA/biocardia-cardiamp-regulatory-progress-hc-wainwright-conference BiopharmaWatch en 2026-09-10T12:30:00.000Z BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-virtual-fireside-chat-september-2026 BiopharmaWatch en 2026-09-10T12:30:00.000Z Intelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ET https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-lucid-ms-phase-2-trial BiopharmaWatch en 2026-09-10T12:30:00.000Z Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market https://www.biopharmawatch.com/news/VNRX/volition-early-stage-cancer-detection-esmo-map BiopharmaWatch en 2026-09-10T12:17:00.000Z Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-next-gen-telomere-targeting-therapies BiopharmaWatch en 2026-09-10T12:15:00.000Z MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026 https://www.biopharmawatch.com/news/ONCY/oncolytics-pelareorep-ras-inhibitor-colorectal-cancer BiopharmaWatch en 2026-09-10T12:15:00.000Z Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer https://www.biopharmawatch.com/news/CADL/candel-therapeutics-appoints-martine-zimmermann BiopharmaWatch en 2026-09-10T12:05:00.000Z Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-dermatology-conferences-2026 BiopharmaWatch en 2026-09-10T12:05:00.000Z Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-stifel-2026-forum BiopharmaWatch en 2026-09-10T12:00:00.000Z Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-arpa-h-give-program-rna-medicines BiopharmaWatch en 2026-09-10T12:00:00.000Z Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines https://www.biopharmawatch.com/news/CMPS/fluence-compass-pathways-comp360-training BiopharmaWatch en 2026-09-10T12:00:00.000Z Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-setmelanotide-espe-2026 BiopharmaWatch en 2026-09-10T12:00:00.000Z Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting https://www.biopharmawatch.com/news/LPCN/lipocine-presentation-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-10T12:00:00.000Z Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/LEGN/legend-biotech-carvykti-update-ims-meeting BiopharmaWatch en 2026-09-10T12:00:00.000Z Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting https://www.biopharmawatch.com/news/HUMA/humacyte-presentation-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-10T12:00:00.000Z Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/ERAS/erasca-multiple-presentations-eortc-nci-aacr-symposium BiopharmaWatch en 2026-09-10T12:00:00.000Z Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium https://www.biopharmawatch.com/news/INAB/in8bio-presentation-hc-wainwright-conference BiopharmaWatch en 2026-09-10T12:00:00.000Z IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-10T12:00:00.000Z Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/ADAG/adagene-third-arc-bio-lead-candidate-selection BiopharmaWatch en 2026-09-10T12:00:00.000Z Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology https://www.biopharmawatch.com/news/SCYX/scynexis-appoints-sanjay-subramanian-cfo BiopharmaWatch en 2026-09-10T12:00:00.000Z SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-10T12:00:00.000Z Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/ICCM/icecure-medical-regulatory-approval-prosense-china BiopharmaWatch en 2026-09-10T11:58:00.000Z IceCure Medical Receives Regulatory Approval to Market ProSense® in China https://www.biopharmawatch.com/news/ELAN/elanco-participate-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-09-10T11:58:00.000Z Elanco to Participate in Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-phase-1-2-trial-authorization BiopharmaWatch en 2026-09-10T11:33:00.000Z CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder https://www.biopharmawatch.com/news/HELP/helus-pharma-participate-morgan-stanley-conference BiopharmaWatch en 2026-09-10T11:30:29.000Z Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York https://www.biopharmawatch.com/news/AGEN/agenus-three-year-survival-data-igcs-2026 BiopharmaWatch en 2026-09-10T11:30:00.000Z Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 https://www.biopharmawatch.com/news/MDCX/medicus-pharma-publishes-abridged-final-phase-2-skinject-clinical-study BiopharmaWatch en 2026-09-10T11:30:00.000Z Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-10T11:30:00.000Z TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/IMRX/immuneering-aacr-conference-atebimetinib-pancreatic-cancer BiopharmaWatch en 2026-09-10T11:30:00.000Z Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival https://www.biopharmawatch.com/news/CRVO/cervomed-phase-2a-trial-neflamapimod-nfvppa-results BiopharmaWatch en 2026-09-10T11:30:00.000Z CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026 https://www.biopharmawatch.com/news/CNSY/cerenome-announces-financing-facility-royalty-repayment BiopharmaWatch en 2026-09-10T11:15:00.000Z Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-fda-clearance-prt13722 BiopharmaWatch en 2026-09-10T11:01:00.000Z Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader https://www.biopharmawatch.com/news/STAA/staaar-surgical-global-report-lens-correction BiopharmaWatch en 2026-09-10T11:00:00.000Z STAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision Correction https://www.biopharmawatch.com/news/ALKS/alkermes-launch-pathways-research-awards-2026 BiopharmaWatch en 2026-09-10T11:00:00.000Z Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-phase-3-data-psych-congress-2026 BiopharmaWatch en 2026-09-10T11:00:00.000Z Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026 https://www.biopharmawatch.com/news/NKTX/nkarta-september-investor-conferences-2026 BiopharmaWatch en 2026-09-10T11:00:00.000Z Nkarta to Participate in September Investor Conferences https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-dreams-grant-recipients-2026 BiopharmaWatch en 2026-09-10T11:00:00.000Z Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program https://www.biopharmawatch.com/news/LH/labcorp-strategic-priorities-2026-investor-day BiopharmaWatch en 2026-09-10T11:00:00.000Z Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor Day https://www.biopharmawatch.com/news/CLGN/collplant-lightsolver-investor-webinar-september-2026 BiopharmaWatch en 2026-09-10T11:00:00.000Z CollPlant to Host LightSolver Investor Webinar on September 17, 2026 https://www.biopharmawatch.com/news/CTSO/cytosorbents-present-h-c-wainwright-28th-annual-global-investment-conference BiopharmaWatch en 2026-09-10T11:00:00.000Z CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-10T11:00:00.000Z Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/KMDA/kamada-presents-hc-wainwright-investment-conference BiopharmaWatch en 2026-09-10T11:00:00.000Z Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/CMPS/compass-pathways-grant-program-psychedelic-training BiopharmaWatch en 2026-09-10T10:35:00.000Z Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training https://www.biopharmawatch.com/news/CMPS/compass-pathways-investor-conferences-september-2023 BiopharmaWatch en 2026-09-10T10:30:00.000Z Compass Pathways to Participate in Investor Conferences the Week of September 14th https://www.biopharmawatch.com/news/AXGN/axogen-pricing-public-offering-common-stock BiopharmaWatch en 2026-09-10T10:01:00.000Z Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock https://www.biopharmawatch.com/news/AXGN/axogen-acquires-biocircuit-technologies BiopharmaWatch en 2026-09-10T10:00:00.000Z Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies https://www.biopharmawatch.com/news/KMTS/kestra-names-daniel-finney-vp-research-development BiopharmaWatch en 2026-09-10T10:00:00.000Z Kestra Names Daniel Finney Vice President of Research & Development https://www.biopharmawatch.com/news/IPHA/innate-pharma-conference-call-september-2026 BiopharmaWatch en 2026-09-10T05:00:00.000Z Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update https://www.biopharmawatch.com/news/IRON/disc-medicine-restore-pv-phase-2-results BiopharmaWatch en 2026-09-09T23:25:00.000Z Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting https://www.biopharmawatch.com/news/NVRS/noveris-health-sciences-2026-meeting-results BiopharmaWatch en 2026-09-09T21:05:00.000Z Noveris Health Sciences Announces Results of 2026 Annual General and Special Meeting https://www.biopharmawatch.com/news/ACTU/actuate-present-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-09T21:00:00.000Z Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/INM/inmed-fiscal-2026-results-mentari-merger-update BiopharmaWatch en 2026-09-09T20:30:00.000Z InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-morgan-stanley-conference BiopharmaWatch en 2026-09-09T20:30:00.000Z Phibro Animal Health Corporation to Participate in Morgan Stanley Annual Global Healthcare Conference https://www.biopharmawatch.com/news/SI/shoulder-innovations-partnership-alm-ortho BiopharmaWatch en 2026-09-09T20:24:00.000Z Shoulder Innovations Announces Exclusive Partnership with ALM Ortho to Introduce Bespoke Solution for Complex Shoulder Reconstruction Procedures https://www.biopharmawatch.com/news/LEXX/lexaria-closes-warrant-exercise-5-9-million BiopharmaWatch en 2026-09-09T20:20:03.000Z Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds https://www.biopharmawatch.com/news/COO/coopercompanies-third-quarter-2026-results BiopharmaWatch en 2026-09-09T20:17:00.000Z CooperCompanies Announces Third Quarter 2026 Results https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-q1-fiscal-2027-results BiopharmaWatch en 2026-09-09T20:15:00.000Z Kewaunee Scientific Reports Results for First Quarter of Fiscal Year 2027 https://www.biopharmawatch.com/news/BKD/brookdale-reports-august-2026-occupancy BiopharmaWatch en 2026-09-09T20:15:00.000Z Brookdale Reports August 2026 Occupancy https://www.biopharmawatch.com/news/NBTX/nanobiotix-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-09T20:15:00.000Z NANOBIOTIX Participera à la Conférence H.C. Wainwright 28th Annual Global Investment https://www.biopharmawatch.com/news/NBTX/nanobiotix-hc-wainwright-investment-conference-2026 BiopharmaWatch en 2026-09-09T20:15:00.000Z NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-presentation-hc-wainwright-conference BiopharmaWatch en 2026-09-09T20:11:00.000Z Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/PRTA/prothena-hc-wainwright-investment-conference BiopharmaWatch en 2026-09-09T20:05:00.000Z Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/ELMD/electromed-participate-hc-wainwright-ld-micro-conference BiopharmaWatch en 2026-09-09T20:05:00.000Z Electromed, Inc. to Participate in the H.C. Wainwright 28th Annual Global Investment Conference and LD Micro 20th Annual Main Event https://www.biopharmawatch.com/news/MGNX/macrogenics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-09T20:05:00.000Z MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/IPSC/century-therapeutics-appoints-joseph-truitt-board BiopharmaWatch en 2026-09-09T20:05:00.000Z Century Therapeutics Appoints Joseph Truitt to Board of Directors https://www.biopharmawatch.com/news/ASND/ascendis-transcon-cnp-infant-data-espe-2026 BiopharmaWatch en 2026-09-09T20:01:00.000Z First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026 https://www.biopharmawatch.com/news/DGX/apple-health-app-quest-diagnostics-labs BiopharmaWatch en 2026-09-09T20:01:00.000Z Apple Health app Users to be Able to Order Labs from Quest Diagnostics https://www.biopharmawatch.com/news/AMGN/amgen-presents-morgan-stanley-global-healthcare-conference BiopharmaWatch en 2026-09-09T20:01:00.000Z AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-attend-morgan-stanley-conference-2026 BiopharmaWatch en 2026-09-09T20:01:00.000Z Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference https://www.biopharmawatch.com/news/GNLX/genelux-olvi-vec-small-cell-lung-cancer-response BiopharmaWatch en 2026-09-09T20:01:00.000Z Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy https://www.biopharmawatch.com/news/GH/guardant-health-2026-wclc-abstracts BiopharmaWatch en 2026-09-09T19:46:00.000Z Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer https://www.biopharmawatch.com/news/MRVL/marvel-biosciences-private-placement-extension BiopharmaWatch en 2026-09-09T18:37:00.000Z Marvel Biosciences annonce la prolongation de la date limite de clôture du placement privé https://www.biopharmawatch.com/news/MRVL/marvel-biosciences-announces-extension-closing-date-private-placement BiopharmaWatch en 2026-09-09T18:32:00.000Z Marvel Biosciences Announces Extension to Closing Date of Private Placement https://www.biopharmawatch.com/news/NTHI/neonc-raises-15-million-phase-2a-data BiopharmaWatch en 2026-09-09T13:35:00.000Z NeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data https://www.biopharmawatch.com/news/SILO/silo-pharma-nasal-innovation-forum-2026 BiopharmaWatch en 2026-09-09T13:15:00.000Z Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum https://www.biopharmawatch.com/news/SI/catalyst-orthoscience-settlement-patent-litigation BiopharmaWatch en 2026-09-09T13:06:00.000Z Catalyst OrthoScience Announces Settlement of Patent Litigation with Shoulder Innovations https://www.biopharmawatch.com/news/ASBP/aspire-lakewood-holdings-share-repurchase-program BiopharmaWatch en 2026-09-09T13:03:48.043Z Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase Program https://www.biopharmawatch.com/news/AIM/aim-immunotech-ampligen-pancreatic-cancer-update BiopharmaWatch en 2026-09-09T13:03:00.000Z AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video https://www.biopharmawatch.com/news/GERN/updated-analysis-imetelstat-myelofibrosis-soho-2026 BiopharmaWatch en 2026-09-09T13:00:00.000Z September 9, 2026 https://www.biopharmawatch.com/news/LH/great-point-partners-sells-mlm-medical-labs-labcorp BiopharmaWatch en 2026-09-09T13:00:00.000Z Great Point Partners III Sells MLM Medical Labs to Labcorp https://www.biopharmawatch.com/news/GOSS/gossamer-bio-reverse-stock-split BiopharmaWatch en 2026-09-09T13:00:00.000Z Gossamer Bio Announces 1-for-80 Reverse Stock Split https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-jefferies-conference-2026 BiopharmaWatch en 2026-09-09T13:00:00.000Z Acadia Healthcare to Participate in 2026 Jefferies Healthcare Services and Technology Conference https://www.biopharmawatch.com/news/CVS/cvs-health-project-health-20-years-free-screenings BiopharmaWatch en 2026-09-09T13:00:00.000Z CVS Health marks 20 years of free community health screening program as new survey reveals many U.S. adults still face barriers to preventive health screenings https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-september-2026-conferences BiopharmaWatch en 2026-09-09T13:00:00.000Z Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences https://www.biopharmawatch.com/news/FEMY/femasys-capexmd-partnership-fertility-access BiopharmaWatch en 2026-09-09T13:00:00.000Z Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio https://www.biopharmawatch.com/news/SCNX/scienture-presentation-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-09T12:55:00.000Z SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 https://www.biopharmawatch.com/news/JUMP/leveljump-announces-management-change BiopharmaWatch en 2026-09-09T12:37:00.000Z LevelJump Announces Management Change https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-breast-cancer-vaccine-bloomberg-tv BiopharmaWatch en 2026-09-09T12:35:00.000Z Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV https://www.biopharmawatch.com/news/TRIB/trinity-biotech-trinovium-contract-red-team-investments BiopharmaWatch en 2026-09-09T12:30:00.000Z Trinity Biotech’s Trinovium Subsidiary Signs Contract to Supply Red Team Investments with Advanced Liquid Cooling Solutions for AI Data Center Infrastructure https://www.biopharmawatch.com/news/IMNN/imunon-rd-day-2026-imnn-001-progress BiopharmaWatch en 2026-09-09T12:30:00.000Z IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-phase-1b-study-prp-2027 BiopharmaWatch en 2026-09-09T12:30:00.000Z Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027 https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-fda-clearance-ms-trials BiopharmaWatch en 2026-09-09T12:30:00.000Z Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment https://www.biopharmawatch.com/news/CTKB/sysmex-cytek-collaboration-clinical-flow-cytometry BiopharmaWatch en 2026-09-09T12:30:00.000Z Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry https://www.biopharmawatch.com/news/XERS/xeris-webinar-xp-8121-development-program BiopharmaWatch en 2026-09-09T12:30:00.000Z Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism https://www.biopharmawatch.com/news/WGS/genedx-beren-therapeutics-launch-npc-genomecomplete BiopharmaWatch en 2026-09-09T12:30:00.000Z GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C https://www.biopharmawatch.com/news/FEED/envue-medical-resumes-commercial-shipments-painshield BiopharmaWatch en 2026-09-09T12:30:00.000Z ENvue Medical Resumes U.S. Commercial Shipments of NanoVibronix PainShield® and Begins Fulfilling Open Distributor Orders https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-fda-510k-drug-screening BiopharmaWatch en 2026-09-09T12:30:00.000Z Intelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance https://www.biopharmawatch.com/news/TAK/oveporexton-phase-3-narcolepsy-results BiopharmaWatch en 2026-09-09T12:24:00.000Z New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life https://www.biopharmawatch.com/news/INMD/inmode-launches-morpheus8-cool-rf-microneedling BiopharmaWatch en 2026-09-09T12:05:00.000Z InMode Advances RF Microneedling Comfort with the Launch of Morpheus8 Cool https://www.biopharmawatch.com/news/AEON/aeon-positive-pilot-results-abp-450-botox BiopharmaWatch en 2026-09-09T12:00:42.000Z AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX® https://www.biopharmawatch.com/news/NTHI/neonc-technologies-15-million-offering BiopharmaWatch en 2026-09-09T12:00:39.000Z NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-appoints-robert-redfield-cso BiopharmaWatch en 2026-09-09T12:00:00.000Z Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer https://www.biopharmawatch.com/news/KAPA/kairos-pharma-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-09T12:00:00.000Z Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/TWST/twist-bioscience-baird-2026-conference BiopharmaWatch en 2026-09-09T12:00:00.000Z Twist Bioscience to Present at Baird 2026 Global Healthcare Conference https://www.biopharmawatch.com/news/MTVA/metavia-preclinical-findings-da-1726-waist-circumference BiopharmaWatch en 2026-09-09T12:00:00.000Z MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction https://www.biopharmawatch.com/news/ECOR/electrocore-appoints-co-ceos-joshua-lev-mike-fox BiopharmaWatch en 2026-09-09T12:00:00.000Z electroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers https://www.biopharmawatch.com/news/INMB/inmune-bio-presentation-hc-wainwright-conference BiopharmaWatch en 2026-09-09T12:00:00.000Z INmune Bio to Present at the H.C. Wainwright Global Investment Conference https://www.biopharmawatch.com/news/AKTS/aktis-oncology-september-investor-conferences BiopharmaWatch en 2026-09-09T12:00:00.000Z Aktis Oncology to Present at Upcoming September Investor Conferences https://www.biopharmawatch.com/news/INAB/in8bio-appoints-oxana-polyakova-svp-research-development BiopharmaWatch en 2026-09-09T12:00:00.000Z IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-09T12:00:00.000Z Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/ADAG/adagene-exelixis-safebody-antibody-drug-conjugate BiopharmaWatch en 2026-09-09T12:00:00.000Z Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates https://www.biopharmawatch.com/news/HUMA/humacyte-fda-authorization-symvess-shelf-life-extension BiopharmaWatch en 2026-09-09T12:00:00.000Z Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months https://www.biopharmawatch.com/news/PRQR/proqr-phase-1-study-ax-0811-investor-event-2026 BiopharmaWatch en 2026-09-09T12:00:00.000Z ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026 https://www.biopharmawatch.com/news/HELP/helus-pharma-hc-wainwright-investment-conference-2026 BiopharmaWatch en 2026-09-09T11:30:30.000Z Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-first-patient-dosed-pnoc035-study BiopharmaWatch en 2026-09-09T11:30:00.000Z Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-eocene-rebranding-eocn BiopharmaWatch en 2026-09-09T11:30:00.000Z Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-appoints-james-treat-cmo BiopharmaWatch en 2026-09-09T11:30:00.000Z Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer https://www.biopharmawatch.com/news/CNTX/context-therapeutics-phase-1-trial-ct-202 BiopharmaWatch en 2026-09-09T11:30:00.000Z Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202 https://www.biopharmawatch.com/news/NGEN/nervgen-rd-day-september-2026 BiopharmaWatch en 2026-09-09T11:30:00.000Z NervGen to Host Inaugural R&D Day on September 30, 2026 https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-09T11:27:00.000Z Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/ACB/aurora-appoints-executive-global-commercial-cannabis BiopharmaWatch en 2026-09-09T11:05:00.000Z Aurora Appoints Seasoned Biopharmaceutical Executive to Lead Commercial Acceleration of Global Medical Cannabis Business https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-fireside-chat-wells-fargo-conference BiopharmaWatch en 2026-09-09T11:00:52.000Z X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/CVS/cvs-health-20-years-free-community-health-screenings BiopharmaWatch en 2026-09-09T11:00:00.000Z CVS Health Marks 20 Years of Free Community Health Screening Program As New Survey Reveals Many U.S. Adults Still Face Barriers to Preventive Health Screenings https://www.biopharmawatch.com/news/CANF/can-fite-namodenoson-improvement-cirrhosis-liver-transplant BiopharmaWatch en 2026-09-09T11:00:00.000Z Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation https://www.biopharmawatch.com/news/SPTX/seaport-therapeutics-positive-results-glyphallo-trial BiopharmaWatch en 2026-09-09T11:00:00.000Z Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-phase-2-surf302-results-dabogratinib BiopharmaWatch en 2026-09-09T11:00:00.000Z Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-presentation-international-congress BiopharmaWatch en 2026-09-09T11:00:00.000Z Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society https://www.biopharmawatch.com/news/OKYO/okyo-pharma-presents-at-escrs-2026 BiopharmaWatch en 2026-09-09T11:00:00.000Z OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026 https://www.biopharmawatch.com/news/KURA/kura-oncology-launches-caspian-therapeutics-diabetes BiopharmaWatch en 2026-09-09T11:00:00.000Z Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes https://www.biopharmawatch.com/news/RZLT/rezolute-fda-review-phase-3-sunrize-study-congenital-hyperinsulinism BiopharmaWatch en 2026-09-09T11:00:00.000Z Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-positive-data-micvo-head-neck-cancer BiopharmaWatch en 2026-09-09T11:00:00.000Z Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) https://www.biopharmawatch.com/news/MSLE/satellos-announces-forazapadin-international-name BiopharmaWatch en 2026-09-09T11:00:00.000Z Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247 https://www.biopharmawatch.com/news/FATE/fate-therapeutics-encore-clinical-data-2026 BiopharmaWatch en 2026-09-09T11:00:00.000Z Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting https://www.biopharmawatch.com/news/MPLT/maplight-therapeutics-investor-conference-participation BiopharmaWatch en 2026-09-09T11:00:00.000Z MapLight Therapeutics to Participate in Upcoming Investor Conference https://www.biopharmawatch.com/news/ACTU/actuate-preclinical-data-elraglusib-ras-inhibitors BiopharmaWatch en 2026-09-09T11:00:00.000Z Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib https://www.biopharmawatch.com/news/IRD/opus-genetics-phase-1-2-trial-opgx-best1-results BiopharmaWatch en 2026-09-09T11:00:00.000Z Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027 https://www.biopharmawatch.com/news/RADX/radiopharm-rad301-positive-phase-1-trial-data BiopharmaWatch en 2026-09-09T11:00:00.000Z Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma https://www.biopharmawatch.com/news/ZOMDF/zomedica-webinar-marketing-engine-september-2026 BiopharmaWatch en 2026-09-09T10:33:51.446Z Zomedica Announces "Fourth Friday at Four" Webinar on September 25, 2026: Inside Zomedica’s Marketing Engine: How Demand Becomes Revenue https://www.biopharmawatch.com/news/CMPS/compass-pathways-comp360-phase-3-results BiopharmaWatch en 2026-09-09T10:30:00.000Z Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year https://www.biopharmawatch.com/news/HIT/health-in-tech-newsweeks-greatest-mid-market-companies-2026 BiopharmaWatch en 2026-09-09T10:30:00.000Z Health In Tech Named to Newsweek's America's Greatest Mid-Market Companies 2026 https://www.biopharmawatch.com/news/MNKD/mannkind-rose-pharma-licensing-agreement-glp1 BiopharmaWatch en 2026-09-09T10:30:00.000Z MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management https://www.biopharmawatch.com/news/TLX/telix-present-morgan-stanley-24th-annual-global-healthcare-conference-h BiopharmaWatch en 2026-09-09T10:30:00.000Z Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/QAI/qscreen-ai-closing-final-tranche-private-placement BiopharmaWatch en 2026-09-09T10:15:00.000Z QScreen AI Announces Closing of Final Tranche of Non-Brokered Private Placement https://www.biopharmawatch.com/news/RVTY/revvity-acquire-human-cell-design-metabolic-disease-drug-discovery BiopharmaWatch en 2026-09-09T10:00:00.000Z Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery https://www.biopharmawatch.com/news/IDYA/first-patient-dosed-optimum-11-trial-darovasertib-crizotinib BiopharmaWatch en 2026-09-09T10:00:00.000Z IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma https://www.biopharmawatch.com/news/RDNT/radnet-presentation-morgan-stanley-healthcare-conference-2026 BiopharmaWatch en 2026-09-09T10:00:00.000Z RadNet, Inc. to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16th, 2026 https://www.biopharmawatch.com/news/RDNT/radnet-free-prostate-cancer-webinar-september-2026 BiopharmaWatch en 2026-09-09T10:00:00.000Z RadNet to Host Free Prostate Cancer Webinar on September 19, 2026 https://www.biopharmawatch.com/news/COSM/cosmos-health-launches-c-scrubvet-uk-animal-health-market BiopharmaWatch en 2026-09-09T09:30:00.000Z Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market https://www.biopharmawatch.com/news/MBX/microbix-qualifies-supplier-dx-test-makers BiopharmaWatch en 2026-09-09T07:00:00.000Z Microbix Qualifies as Supplier for Five Major Dx Test-Makers Product Lines for Support of Leading IVD Manufacturers https://www.biopharmawatch.com/news/EVO/evotec-phase-1-trial-orthopoxvirus-antibodies BiopharmaWatch en 2026-09-09T06:00:00.000Z Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies https://www.biopharmawatch.com/news/EVMN/evommune-evo756-phase-2b-results-atopic-dermatitis BiopharmaWatch en 2026-09-08T21:43:00.000Z Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis https://www.biopharmawatch.com/news/THC/tenet-upsizing-pricing-senior-notes-offering BiopharmaWatch en 2026-09-08T21:00:00.000Z Tenet Announces Upsizing and Pricing of Its $2.0 Billion Private Offering of Senior Notes https://www.biopharmawatch.com/news/APMD/apnimed-reports-q2-2026-results-corporate-update BiopharmaWatch en 2026-09-08T20:39:00.000Z Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/blog/most-crowded-drug-targets-biotech-2026 BiopharmaWatch en 2026-09-08T20:38:50.515Z The Most Crowded Drug Targets in Biotech: 19 Companies Are Chasing CD19 https://www.biopharmawatch.com/news/WRBY/warby-parker-goldman-sachs-conference-2026 BiopharmaWatch en 2026-09-08T20:30:00.000Z Warby Parker Announces Participation in the Goldman Sachs 33rd Annual Global Retailing Conference https://www.biopharmawatch.com/news/BFLY/butterfly-network-morgan-stanley-healthcare-conference-2026 BiopharmaWatch en 2026-09-08T20:30:00.000Z Butterfly Network to Participate in Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026 https://www.biopharmawatch.com/news/ZBH/zimmer-biomet-leadership-promotions-commercial-transformation BiopharmaWatch en 2026-09-08T20:30:00.000Z Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation https://www.biopharmawatch.com/news/IMA/imagene-bio-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-08T20:30:00.000Z ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York https://www.biopharmawatch.com/news/BKD/brookdale-present-2026-jefferies-bank-america-conference BiopharmaWatch en 2026-09-08T20:15:00.000Z Brookdale to Present at the 2026 Jefferies Healthcare Services and Technology Conference and the Bank of America Global Real Estate Conference 2026 https://www.biopharmawatch.com/news/INCR/intercure-regains-compliance-nasdaq-minimum-bid-price BiopharmaWatch en 2026-09-08T20:12:00.000Z InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement https://www.biopharmawatch.com/news/FBIO/journey-medical-september-2026-investor-conferences BiopharmaWatch en 2026-09-08T20:05:00.000Z Journey Medical Corporation to Participate in September 2026 Investor Conferences https://www.biopharmawatch.com/news/STVN/stevanato-group-investor-conferences-2023 BiopharmaWatch en 2026-09-08T20:05:00.000Z Stevanato Group to Participate in Two Upcoming Investor Conferences https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-08T20:05:00.000Z Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/BBOT/bbot-announces-bbo-8520-data-strategic-focus-nsclc BiopharmaWatch en 2026-09-08T20:05:00.000Z BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers https://www.biopharmawatch.com/news/CARL/carlsmed-announces-coo-appointment BiopharmaWatch en 2026-09-08T20:05:00.000Z Carlsmed, Inc. Announces Chief Operating Officer Appointment https://www.biopharmawatch.com/news/DERM/journey-medical-september-2026-investor-conferences BiopharmaWatch en 2026-09-08T20:05:00.000Z Journey Medical Corporation to Participate in September 2026 Investor Conferences https://www.biopharmawatch.com/news/INNV/innovage-financial-results-fiscal-year-2026 BiopharmaWatch en 2026-09-08T20:05:00.000Z InnovAge Announces Financial Results for the Fourth Quarter and Fiscal Year Ended June 30, 2026 https://www.biopharmawatch.com/news/TARA/protara-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-08T20:05:00.000Z Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-analyst-day-cmp-002-syngap1 BiopharmaWatch en 2026-09-08T20:05:00.000Z CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026 https://www.biopharmawatch.com/news/SI/shoulder-innovations-settlement-patent-litigation-catalyst BiopharmaWatch en 2026-09-08T20:05:00.000Z Shoulder Innovations Announces Settlement of Patent Litigation with Catalyst OrthoScience https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-presentation-cantor-conference-2026 BiopharmaWatch en 2026-09-08T20:05:00.000Z Tyra Biosciences to Present at the Cantor Global Healthcare Conference https://www.biopharmawatch.com/news/BRVE/braveheart-bio-q2-2026-financial-results-update BiopharmaWatch en 2026-09-08T20:03:00.000Z Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/ALGN/align-technology-financial-conference-presentation BiopharmaWatch en 2026-09-08T20:01:00.000Z Align Technology to Speak at Upcoming Financial Conference https://www.biopharmawatch.com/news/STAA/staars-new-cfo-david-bailey-appointment BiopharmaWatch en 2026-09-08T20:01:00.000Z STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer https://www.biopharmawatch.com/news/ASND/ascendis-pharma-morgan-stanley-conference-2026 BiopharmaWatch en 2026-09-08T20:01:00.000Z Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-webcast-phase-1-micvo-update BiopharmaWatch en 2026-09-08T20:01:00.000Z Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) https://www.biopharmawatch.com/news/KROS/keros-therapeutics-share-repurchase-authorization BiopharmaWatch en 2026-09-08T20:01:00.000Z Keros Therapeutics Announces $5 Million Share Repurchase Authorization https://www.biopharmawatch.com/news/LKFT/lakefront-global-healthcare-conference-2026 BiopharmaWatch en 2026-09-08T20:01:00.000Z Lakefront presenteert op de 24e jaarlijkse Global Healthcare Conference van Morgan Stanley https://www.biopharmawatch.com/news/LKFT/lakefront-presents-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-09-08T20:01:00.000Z Lakefront to Present at the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/AHCO/adapthealth-appoints-harriss-currie-cfo BiopharmaWatch en 2026-09-08T20:00:00.000Z AdaptHealth Appoints Harriss Currie as Chief Financial Officer https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-gilead-hsv-helicase-primase BiopharmaWatch en 2026-09-08T20:00:00.000Z Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program https://www.biopharmawatch.com/news/IVA/inventiva-abstracts-paris-mash-2026 BiopharmaWatch en 2026-09-08T20:00:00.000Z Inventiva présentera plusieurs abstracts lors du Congrès Paris MASH 2026 https://www.biopharmawatch.com/news/IVA/inventiva-presents-abstracts-paris-mash-2026 BiopharmaWatch en 2026-09-08T20:00:00.000Z Inventiva to Present Multiple Abstracts at Paris MASH 2026 https://www.biopharmawatch.com/news/GH/guardant-health-americas-most-innovative-businesses BiopharmaWatch en 2026-09-08T18:38:00.000Z Business Insider Names Guardant Health One of America's Most Innovative Businesses